Does the media prefer ALNY or IONS?

In the previous week, Ionis Pharmaceuticals had 5 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 29 mentions for Ionis Pharmaceuticals and 24 mentions for Alnylam Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.69 beat Alnylam Pharmaceuticals' score of 0.50 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Ionis Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IONS or BIIB?

In the previous week, Biogen had 25 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 54 mentions for Biogen and 29 mentions for Ionis Pharmaceuticals. Biogen's average media sentiment score of 0.79 beat Ionis Pharmaceuticals' score of 0.69 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 26 Very Positive mention(s) 4 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor IONS or INCY?

In the previous week, Incyte had 17 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 46 mentions for Incyte and 29 mentions for Ionis Pharmaceuticals. Incyte's average media sentiment score of 0.89 beat Ionis Pharmaceuticals' score of 0.69 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 23 Very Positive mention(s) 2 Positive mention(s) 14 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer UTHR or IONS?

In the previous week, United Therapeutics had 3 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 32 mentions for United Therapeutics and 29 mentions for Ionis Pharmaceuticals. United Therapeutics' average media sentiment score of 1.17 beat Ionis Pharmaceuticals' score of 0.69 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 24 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Ionis Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IONS or NBIX?

In the previous week, Ionis Pharmaceuticals had 12 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 29 mentions for Ionis Pharmaceuticals and 17 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.01 beat Ionis Pharmaceuticals' score of 0.69 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ionis Pharmaceuticals (IONS) Competitors

$53.28 -0.76 (-1.41%)

Closing price 07/30/2026 04:00 PM Eastern

Extended Trading

$53.35 +0.07 (+0.13%)

As of 07/30/2026 07:55 PM Eastern

Compare

IONS vs. ALNY, BIIB, INCY, UTHR, and NBIX

Should you buy Ionis Pharmaceuticals stock or one of its competitors? MarketBeat compares Ionis Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ionis Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market.

Alnylam Pharmaceuticals has a net margin of 11.72% compared to Ionis Pharmaceuticals' net margin of -64.76%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%
Ionis Pharmaceuticals	-64.76%	-106.23%	-16.97%

Alnylam Pharmaceuticals has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	7.39	$313.75M	$3.66	56.14
Ionis Pharmaceuticals	$944M	9.33	-$381.39M	-$2.07	N/A

Alnylam Pharmaceuticals currently has a consensus target price of $445.48, indicating a potential upside of 116.80%. Ionis Pharmaceuticals has a consensus target price of $94.85, indicating a potential upside of 78.02%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Alnylam Pharmaceuticals is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.77

In the previous week, Ionis Pharmaceuticals had 5 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 29 mentions for Ionis Pharmaceuticals and 24 mentions for Alnylam Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.69 beat Alnylam Pharmaceuticals' score of 0.50 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ionis Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alnylam Pharmaceuticals beats Ionis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Biogen?

Ionis Pharmaceuticals (NASDAQ:IONS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Ionis Pharmaceuticals has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Biogen has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

In the previous week, Biogen had 25 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 54 mentions for Biogen and 29 mentions for Ionis Pharmaceuticals. Biogen's average media sentiment score of 0.79 beat Ionis Pharmaceuticals' score of 0.69 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	26 Very Positive mention(s)	4 Positive mention(s)	13 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Ionis Pharmaceuticals currently has a consensus price target of $94.85, indicating a potential upside of 78.02%. Biogen has a consensus price target of $223.36, indicating a potential upside of 7.42%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.77
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	9.33	-$381.39M	-$2.07	N/A
Biogen	$9.89B	3.10	$1.29B	$9.32	22.31

Biogen has a net margin of 8.32% compared to Ionis Pharmaceuticals' net margin of -64.76%. Biogen's return on equity of 11.18% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-106.23%	-16.97%
Biogen	8.32%	11.18%	6.88%

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 1.8% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Biogen beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Incyte?

Ionis Pharmaceuticals (NASDAQ:IONS) and Incyte (NASDAQ:INCY) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Ionis Pharmaceuticals has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market. Comparatively, Incyte has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Incyte has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	9.33	-$381.39M	-$2.07	N/A
Incyte	$5.14B	4.85	$1.29B	$7.08	17.37

Incyte has a net margin of 27.71% compared to Ionis Pharmaceuticals' net margin of -64.76%. Incyte's return on equity of 29.93% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-106.23%	-16.97%
Incyte	27.71%	29.93%	22.88%

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ionis Pharmaceuticals currently has a consensus price target of $94.85, indicating a potential upside of 78.02%. Incyte has a consensus price target of $117.74, indicating a potential downside of 4.27%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.77
Incyte	0 Sell rating(s)	14 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36

In the previous week, Incyte had 17 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 46 mentions for Incyte and 29 mentions for Ionis Pharmaceuticals. Incyte's average media sentiment score of 0.89 beat Ionis Pharmaceuticals' score of 0.69 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	23 Very Positive mention(s)	2 Positive mention(s)	14 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Incyte beats Ionis Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

United Therapeutics has a net margin of 40.62% compared to Ionis Pharmaceuticals' net margin of -64.76%. United Therapeutics' return on equity of 19.24% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Ionis Pharmaceuticals	-64.76%	-106.23%	-16.97%

United Therapeutics currently has a consensus price target of $648.33, indicating a potential upside of 23.30%. Ionis Pharmaceuticals has a consensus price target of $94.85, indicating a potential upside of 78.02%. Given Ionis Pharmaceuticals' higher probable upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.77

United Therapeutics has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.01	$1.33B	$27.09	19.41
Ionis Pharmaceuticals	$944M	9.33	-$381.39M	-$2.07	N/A

United Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

In the previous week, United Therapeutics had 3 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 32 mentions for United Therapeutics and 29 mentions for Ionis Pharmaceuticals. United Therapeutics' average media sentiment score of 1.17 beat Ionis Pharmaceuticals' score of 0.69 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	24 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

United Therapeutics beats Ionis Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Neurocrine Biosciences?

Ionis Pharmaceuticals (NASDAQ:IONS) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Neurocrine Biosciences has a net margin of 21.55% compared to Ionis Pharmaceuticals' net margin of -64.76%. Neurocrine Biosciences' return on equity of 19.79% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-106.23%	-16.97%
Neurocrine Biosciences	21.55%	19.79%	13.82%

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 1.8% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Neurocrine Biosciences has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	9.33	-$381.39M	-$2.07	N/A
Neurocrine Biosciences	$2.86B	6.52	$478.60M	$6.49	28.58

In the previous week, Ionis Pharmaceuticals had 12 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 29 mentions for Ionis Pharmaceuticals and 17 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.01 beat Ionis Pharmaceuticals' score of 0.69 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ionis Pharmaceuticals currently has a consensus price target of $94.85, indicating a potential upside of 78.02%. Neurocrine Biosciences has a consensus price target of $194.05, indicating a potential upside of 4.61%. Given Ionis Pharmaceuticals' higher probable upside, equities analysts plainly believe Ionis Pharmaceuticals is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.77
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96

Ionis Pharmaceuticals has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Summary

Neurocrine Biosciences beats Ionis Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Ionis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IONS vs. The Competition

Export

Metric	Ionis Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.93B	$3.11B	$7.04B	$12.02B
Dividend Yield	N/A	1.99%	2.65%	10.11%
P/E Ratio	-15.40	20.38	27.67	23.56
Price / Sales	9.33	364.16	527.08	94.43
Price / Cash	N/A	34.89	51.74	58.30
Price / Book	17.64	4.13	10.06	5.85
Net Income	-$381.39M	$67.27M	$3.60B	$336.53M
7 Day Performance	-5.78%	-0.40%	0.65%	0.38%
1 Month Performance	-32.87%	-7.31%	-3.30%	-4.97%
1 Year Performance	23.96%	17.49%	24.46%	17.95%

Ionis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IONS Ionis Pharmaceuticals	3.625 of 5 stars	$53.28 -1.4%	$94.85 +78.0%	+22.8%	$8.93B	$944M	N/A	1,402	Trending News Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.5772 of 5 stars	$278.40 +2.4%	$452.13 +62.4%	-39.5%	$36.28B	$3.71B	76.07	2,770	Trending News Analyst Forecast Gap Down
BIIB Biogen	3.4835 of 5 stars	$200.14 -1.0%	$220.57 +10.2%	+64.2%	$29.85B	$9.89B	21.47	7,500	Trending News Earnings Report Analyst Upgrade Gap Down
INCY Incyte	2.8971 of 5 stars	$118.87 +1.0%	$111.10 -6.5%	+58.6%	$23.51B	$5.14B	16.79	2,844	Trending News Earnings Report Analyst Forecast
UTHR United Therapeutics	4.6884 of 5 stars	$527.94 -0.1%	$648.33 +22.8%	+86.5%	$22.43B	$3.18B	19.49	1,400	Positive News Upcoming Earnings Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IONS) was last updated on 7/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ionis Pharmaceuticals (IONS) Competitors

IONS vs. ALNY, BIIB, INCY, UTHR, and NBIX

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

How does Ionis Pharmaceuticals compare to Biogen?

Summary

How does Ionis Pharmaceuticals compare to Incyte?

Summary

How does Ionis Pharmaceuticals compare to United Therapeutics?

Summary

How does Ionis Pharmaceuticals compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IONS vs. The Competition

Ionis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ionis Pharmaceuticals (IONS) Competitors

IONS vs. ALNY, BIIB, INCY, UTHR, and NBIX

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Do institutionals and insiders have more ownership in ALNY or IONS?

Which has more risk and volatility, ALNY or IONS?

Is ALNY or IONS more profitable?

Which has preferable earnings and valuation, ALNY or IONS?

Do analysts prefer ALNY or IONS?

Does the media prefer ALNY or IONS?

Summary

How does Ionis Pharmaceuticals compare to Biogen?

Which has more risk & volatility, IONS or BIIB?

Does the media refer more to IONS or BIIB?

Do analysts prefer IONS or BIIB?

Which has higher earnings and valuation, IONS or BIIB?

Is IONS or BIIB more profitable?

Do institutionals & insiders believe in IONS or BIIB?

Summary

How does Ionis Pharmaceuticals compare to Incyte?

Which has more volatility and risk, IONS or INCY?

Which has higher valuation & earnings, IONS or INCY?

Is IONS or INCY more profitable?

Do insiders & institutionals believe in IONS or INCY?

Do analysts recommend IONS or INCY?

Does the media favor IONS or INCY?

Summary

How does Ionis Pharmaceuticals compare to United Therapeutics?

Do insiders and institutionals have more ownership in UTHR or IONS?

Is UTHR or IONS more profitable?

Do analysts recommend UTHR or IONS?

Which has better valuation and earnings, UTHR or IONS?

Which has more risk & volatility, UTHR or IONS?

Does the media prefer UTHR or IONS?

Summary

How does Ionis Pharmaceuticals compare to Neurocrine Biosciences?

Is IONS or NBIX more profitable?

Do insiders & institutionals believe in IONS or NBIX?

Which has stronger valuation & earnings, IONS or NBIX?

Does the media favor IONS or NBIX?

Do analysts rate IONS or NBIX?

Which has more risk & volatility, IONS or NBIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IONS vs. The Competition

Ionis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools